MyOme announced an investment from Illumina and plans to launch a prospective clinical trial, MyOme’s Proactive Health (MPH), combining whole‑genome sequencing on Illumina’s NovaSeq X with AI risk‑prediction models to evaluate whether genomic screening improves outcomes and reduces costs. MyOme said the study will focus on common chronic conditions and health‑economic endpoints. MyOme CEO Premal Shah framed the program as a test of clinical utility and cost‑saving potential for integrating population genomic data into preventive care. The company emphasized Illumina’s strategic support, which includes sequencing access and collaboration on analytics and commercialization paths. If the trial demonstrates clinical benefit and economic value, the approach could accelerate health‑system adoption of comprehensive genomic screening and shift reimbursement and care‑pathway models for preventive precision medicine.